Mostbeck A, Galvan G, Bauer P, Eber O, Atefie K, Dam K, Feichtinger H, Fritzsche H, Haydl H, Köhn H, König B, Koriska K, Kroiss A, Lind P, Markt B, Maschek W, Pesl H, Ramschak-Schwarzer S, Riccabona G, Stockhammer M, Zechmann W
L. Boltzmann Institut für Nuklearmedizin, Wilhelminenspital, Vienna, Austria.
Eur J Nucl Med. 1998 Apr;25(4):367-74. doi: 10.1007/s002590050234.
Between 1963 and 1990, Austria had iodized salt prophylaxis of endemic goitre with 10 mg KI (7.5 mg I) per kg. This was obviously insufficient, as urinary iodine excretion ranged from 42 to 78 microg I per g of creatinine and goitre in adults remained in the endemic range of 15%-30%. Therefore salt iodization was doubled in 1990. The aim of this study was to assess the annual incidence of different types of hyperthyroidism (HT) before and after this increase in salt iodization. The incidence of HT was recorded in 14 nuclear medicine centres from 1987 to 1995. In five additional centres data were available from 1992 onwards. Data prior to 1992 were documented retrospectively, while those after 1992 were recorded prospectively. The 14 centres drew patients from an area with a population of approximately 4.23 million while all 19 institutes were estimated to cover an area with a population of 5.4 million (the total population of Austria is 7.86 million). A total of 414232 persons were examined for the first time in the participating centres. HT and the type of HT were defined by clinical examination, serum TSH, thyroid hormone levels in blood, ultrasonography, scintigraphy and serum autoantibody titres. HT was classified into immunogenic HT (Graves' or Basedow's disease, GD) and HT with intrinsic thyroid autonomy (uni-, multinodular or disseminated Plummers' disease, PD). HT was also divided into overt (o) or subclinical (sc) disease. The following data were calculated: annual incidence per 100000 and the relative risk (RR) for HT with 95% confidence intervals (CI). In addition, linear trends were calculated for each type of HT by means of logistic regressions. In the 19 centres a total of 47834 patients with HT were registered from 1987 to 1995. PD accounted for 75% of all cases of HT and GD for 19%, while other types of HT were present in 6%. From 1987 to 1989 (time period T0), the annual incidence of oPD was 30.5 (95% CI 29.6-31.5) per 100000. The RR compared to the baseline period T0 was highest in 1992 (1.37; 1.3-1.45) and decreased to 1.17 (1.1-1.24) in 1995. The annual incidence of scPD in T0 was 27.4 (26.5-28.3) per 100000. The RR was highest in 1991 (1.64; 1.56-1.73) and was 1.60 (1. 51-1.69) in 1995. In oPD and scPD a higher RR was observed in persons older than 50 years of age, particularly in men. The incidence of oGD in T0 was 10.4 (9.8-10.9) per 100000; the maximum RR increased to 2.19 (2.01-2.38) in 1993 and decreased to 1.95 (1.78-2.13) in 1995. The incidence of scGD was 1.9 (1.6-2.1) in T0. The maximum RR was observed in 1994 (2.47; 2.04-3.0) and it was still 2.26 (1.85-2.77) in 1995. The increased incidence of oGD and scGD was evenly distributed in all ages and both sexes. The time course of different types of HT following the increase in salt iodization could be divided into two phases: an increase in the incidences of HT with peaks after 1-4 years and a subsequent decrease, the only exception being scGD. The effect was more pronounced in GD than in PD. PD showed an age and gender dependency over time, while GD did not.
1963年至1990年间,奥地利采用每千克加10毫克碘化钾(7.5毫克碘)的方式对地方性甲状腺肿进行碘盐预防。这显然是不够的,因为尿碘排泄量为每克肌酐42至78微克碘,成人甲状腺肿患病率仍处于15% - 30%的地方性流行范围。因此,1990年盐加碘量增加了一倍。本研究的目的是评估盐加碘量增加前后不同类型甲状腺功能亢进症(HT)的年发病率。1987年至1995年期间,在14个核医学中心记录了HT的发病率。另外5个中心从1992年起有相关数据。1992年以前的数据是回顾性记录的,而1992年以后的数据是前瞻性记录的。14个中心的患者来自一个约有423万人口的地区,而所有19个机构估计覆盖一个有540万人口的地区(奥地利总人口为786万)。参与中心共对414232人进行了首次检查。HT及其类型通过临床检查、血清促甲状腺激素、血液中的甲状腺激素水平、超声检查、闪烁扫描和血清自身抗体滴度来定义。HT分为免疫性HT(格雷夫斯病或巴塞多氏病,GD)和具有甲状腺自身自主性的HT(单结节、多结节或弥漫性普卢默病,PD)。HT也分为显性(o)或亚临床(sc)疾病。计算了以下数据:每10万人的年发病率以及HT的相对风险(RR)和95%置信区间(CI)。此外,通过逻辑回归计算了每种类型HT的线性趋势。1987年至1995年期间,19个中心共登记了47834例HT患者。PD占所有HT病例的75%,GD占19%,其他类型的HT占6%。1987年至1989年(时间段T0),oPD的年发病率为每10万人30.5(95%CI 29.6 - 31.5)。与基线期T0相比,RR在1992年最高(1.37;1.3 - 1.45),1995年降至1.17(1.1 - 1.24)。T0期scPD的年发病率为每10万人27.4(26.5 - 28.3)。RR在1991年最高(1.64;1.56 - 1.73),1995年为1.60(1.51 - 1.69)。在oPD和scPD中,50岁以上人群,尤其是男性,RR更高。T0期oGD的年发病率为每10万人10.4(9.8 - 10.9);最大RR在1993年升至2.19(2.01 - 2.38),1995年降至1.95(1.78 - 2.13)。T0期scGD的发病率为1.9(1.6 - 2.1)。最大RR在1994年观察到(2.47;2.04 - 3.0),1995年仍为2.26(1.85 - 2.77)。oGD和scGD发病率的增加在所有年龄和性别中分布均匀。盐加碘量增加后不同类型HT的时间进程可分为两个阶段:HT发病率在1 - 4年后达到峰值然后下降,唯一的例外是scGD。GD的影响比PD更明显。随着时间的推移,PD表现出年龄和性别依赖性,而GD则没有。